1. Suda T, Takahashi N, Martin TJ. Modulation of osteoclast differentiation [published correction appears in Endocr Rev 1992; 13: 191]. Endocr Rev 1992; 13: 66–80. doi: 10.1210/edrv-13-1-66.
2.
Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin / osteoclastogenesis-inhibitory factor and is identical to TRANCE / RANKL. Proc Natl Acad Sci U S A 1998; 95: 3597–3602.
3.
Yasuda H. Discovery of the RANKL/RANK/OPG system [published correction appears in J Bone Miner Metab 2021; 39: 12. doi: 10.1007/s00774-021-01203-8]. J Bone Miner Metab 2021; 39: 2–11. doi: 10.1007/s00774-020-01175-1.
4.
Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007; 9 Suppl 1 (Suppl 1): S1. doi: 10.1186/ar2165.
5.
Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89(2):309–319. doi:10.1016/s0092-8674(00)80209-3.
6.
Hofbauer LC. Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG). Ann Endocrinol (Paris) 2006; 67: 139–141. doi:10.1016/s0003-4266(06)72569-0.
7.
Hofbauer LC, Khosla S, Dunstan CR, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15: 2–12. doi: 10.1359/jbmr.2000.15.1.2.
8.
Tietze H, Pott V, Kanzelmeyer N, et al. LMS-based continuous pediatric reference values for soluble receptor activator of nuclear factor kappa B ligand (sRANKL) and osteoprotegerin (OPG) in the HARP cohort. Osteoporos Int. 2024; 35: 533–542. doi: 10.1007/s00198-023-06959-5.
9.
Brunetti G, D’Amato G, Chiarito M, et al. An update on the role of RANKL-RANK/osteoprotegerin and WNT-ß-catenin signaling pathways in pediatric diseases. World J Pediatr 2019; 15: 4–11. doi: 10.1007/s12519-018-0198-7.
10.
Akhtar Ali S, Kang H, Olney R, et al. Quantifying RANKL and OPG levels in healthy children: A large cross-sectional analysis. Bone 2019; 127: 215–219. doi: 10.1016/j.bone.2019.06.012.
11.
Regev R, Sochett EB, Elia Y, et al. Multicentric carpotarsal osteolysis syndrome (MCTO) with generalized high bone turnover and high serum RANKL: Response to denosumab. Bone Rep 2021; 14: 100747. doi: 10.1016/j.bonr.2021.100747
12.
Kułaga Z, Różdżyńska-Świątkowska A, Grajda A, et al. Siatki centylowe dla oceny wzrastania i stanu odżywienia polskich dzieci i młodzieży od urodzenia do 18 roku życia. Standardy Medyczne Pediatria 2015; 12: 119–135.
13.
Emmanuel M, Bokor BR. Tanner Stages. StatPearls Publishing 2022.
14.
Khalaf RM, Almudhi AA. The effect of vitamin D deficiency on the RANKL/OPG ratio in rats. J Oral Biol Craniofac Res 2022; 12: 228–232. doi: 10.1016/j.jobcr.2022.02.004
15.
Ciancia S, van Rijn RR, Högler W, et al. Osteoporosis in children and adolescents: when to suspect and how to diagnose it. Eur J Pediatr 2022; 181: 2549–2561. doi: 10.1007/s00431-022-04455-2.
16.
Shuhart CR, Yeap SS, Anderson PA, et al. Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics. J Clin Densitom 2019; 22: 453–471. doi: 10.1016/j.jocd.2019.07.001.
17.
Amer OE, Wani K, Ansari MGA, et al. Associations of Bone Mineral Density with RANKL and Osteoprotegerin in Arab Postmenopausal Women: A Cross-Sectional Study. Medicina (Kaunas) 2022; 58: 76. doi: 10.3390/medicina58080976 .
18.
Fahrleitner-Pammer A, Dobnig H, Piswanger-Soelkner C, et al. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. Wien Klin Wochenschr 2003; 115: 291–297. doi: 10.1007/BF03040334.
19.
Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001; 142: 5050–5055. doi: 10.1210/endo.142.12.8536.
20.
Hofbauer LC, Kühne CA, Viereck V. The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 2004; 4: 268–275.
21.
Liu JM, Zhao HY, Ning G, et al. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. Calcif Tissue Int 2005; 76: 1–6. doi: 10.1007/s00223-004-0007-2.
22.
Szulc P, Hofbauer LC, Heufelder AE, et al. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 2001; 86: 3162–3165. doi: 10.1210/jcem.86.7.7657.
23.
Wasilewska A, Rybi-Szuminska AA, Zoch-Zwierz W. Serum osteoprotegrin (OPG) and receptor activator of nuclear factor kappaB (RANKL) in healthy children and adolescents. J Pediatr Endocrinol Metab 2009; 22: 1099–1104. doi: 10.1515/jpem.2009.22.12.1099.
24.
Buzi F, Maccarinelli G, Guaragni B, et al. Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner’s syndrome and rheumatoid arthritis. Clin Endocrinol (Oxf) 2004; 60: 87–91. doi: 10.1111/j.1365-2265.2004.01951.x.
25.
Mitchell JA, Chesi A, Elci O, et al. Genetic Risk Scores Implicated in Adult Bone Fragility Associate With Pediatric Bone Density. J Bone Miner Res 2016; 31: 789–795. doi: 10.1002/jbmr.2744.
26.
Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005; 90: 6323–6331. doi: 10.1210/jc.2005-0794
27.
Dimitri P, Wales JK, Bishop N. Adipokines, bone-derived factors and bone turnover in obese children; evidence for altered fat-bone signalling resulting in reduced bone mass. Bone 2011; 48: 189–196. doi: 10.1016/j.bone.2010.09.034.
ENGLISH
